There is no permanent cure for depression in the way antibiotics cure an infection. But depression can be treated effectively, and many people reach full remission, a state where symptoms drop to minimal or near-zero levels. The more precise question, and the more useful one, is how reliably treatments can get you to remission and how long that remission can last.
Why Doctors Talk About Remission, Not Cure
Depression has no blood test or biomarker that signals “disease present” or “disease gone.” Instead, clinicians measure symptom severity using standardized questionnaires. Remission is typically defined as scoring at or below a threshold on these scales, essentially having no more than minimal symptoms. Recovery means sustaining that remission for at least two months.
The distinction matters because depression tends to be a recurring condition. After a first episode resolves, roughly 37 to 39% of people relapse within 12 months. Over two years, that number climbs to around 43 to 66%, depending on the treatment used and how it was delivered. Each additional episode raises the odds of another one. This pattern is the core reason professionals avoid the word “cure.” It’s not that people can’t feel well again. They absolutely can. It’s that the vulnerability often remains, and managing it is part of the picture long term.
How Well Standard Treatments Work
The largest real-world trial of antidepressant treatment, known as STAR*D, followed thousands of patients through multiple rounds of medication. With a first medication, about 28 to 33% of people achieved remission. Those who didn’t improve could try a different drug or add a second one. Each subsequent step helped some additional patients, but the remission rates for later options dropped, falling to around 12 to 20% by the third and fourth attempts. The cumulative picture is more encouraging than any single step: across all rounds, roughly two-thirds of participants eventually improved substantially.
Cognitive behavioral therapy (CBT) performs comparably to medication for many people, with a moderate effect on symptoms. Where it stands out is in what happens after treatment ends. In one trial, patients who started with CBT and then added medication when needed achieved remission rates as high as 89%, and their recurrence rate afterward was about 15%. Patients who took the opposite path, medication first then CBT, saw a recurrence rate of 22%. The combination of both approaches consistently outperforms either one alone.
The World Health Organization recommends continuing antidepressant medication for at least six months after reaching remission. This continuation phase significantly reduces the chance of relapse compared to stopping early. For people with multiple past episodes, longer maintenance treatment is common.
Exercise as a Treatment, Not Just a Habit
A large network analysis published in The BMJ compared dozens of exercise types against active controls and standard treatments. Walking or jogging produced a moderate reduction in depression symptoms, comparable in effect size to CBT and actually larger than the effect measured for SSRIs alone in the same analysis. Dance showed the strongest effect of any exercise type. Yoga, strength training, tai chi, and mixed aerobic exercise all produced meaningful reductions as well.
Combining exercise with medication or psychotherapy amplified the benefit. Exercise paired with SSRIs, or aerobic exercise paired with talk therapy, both showed moderate, clinically meaningful effects. This doesn’t mean exercise replaces other treatments, but it is a genuine intervention with measurable impact on the brain’s stress and reward systems, not just a lifestyle suggestion.
Options for Treatment-Resistant Depression
When multiple medications and therapy haven’t worked, the diagnosis shifts to treatment-resistant depression (TRD). Several options exist for this group, and they’re improving.
Transcranial magnetic stimulation (TMS) uses focused magnetic pulses to stimulate specific brain areas. The standard FDA-approved protocol takes about six weeks of daily sessions. Roughly half of patients who undergo it improve, and about a third reach full remission. An accelerated version developed at Stanford, which compresses the treatment into days rather than weeks, showed remission in nearly 80% of participants in a controlled study, though it is still being studied in broader populations.
A nasal spray delivering a form of ketamine has been approved specifically for treatment-resistant depression. Real-world data from multiple countries show a consistent pattern: remission rates start modest during the first month of treatment, often around 10 to 20%, then climb significantly over three to six months of continued use, reaching 38 to 53% depending on the study and patient population. Results vary, and response tends to be better in patients who haven’t already tried many other interventions.
Psilocybin and What Early Data Shows
Clinical trials are testing psilocybin, the active compound in certain mushrooms, as a treatment for severe depression. A pilot study in military veterans with severe treatment-resistant depression, people who had failed five or more prior treatments, gave a single 25-milligram dose and tracked outcomes for a full year. At three weeks, 53% of participants met remission criteria. At six months, 50% were still in remission. By 12 months, that number had dropped to 30%, with the antidepressant effect fading more noticeably after the nine-month mark.
These results are striking given how severely ill the participants were, but the study was small (15 people) and had no placebo group. Psilocybin is not approved for depression treatment and is only available through clinical trials or specific regulatory exemptions. Larger trials are underway.
What Long-Term Management Looks Like
For many people, the practical reality of managing depression resembles managing other chronic conditions like asthma or high blood pressure. You find a combination of treatments that works, you maintain them, and you adjust when things shift. That combination might be medication alone, therapy alone, or both together with regular exercise.
The relapse numbers can sound discouraging, but context helps. Guided, structured CBT delivered at the right intensity lowers the 12-month relapse rate to around 21%, compared to 35 to 53% for less intensive or self-guided approaches. Staying on medication after remission cuts relapse risk further. Each protective layer you add, therapy skills, physical activity, medication when appropriate, social support, reduces the likelihood that a future episode takes hold or lasts as long.
Depression is not something you simply power through, and it’s not a life sentence either. The honest answer is that it can’t be cured in the permanent, one-and-done sense, but it can be treated well enough that many people live years or even decades without significant symptoms. The tools for getting there are more effective and more varied than they were even ten years ago.